2414962-49-3
Chemical Structure
Sirexatamab
Synonym(s): DKN-01; LY-2812176
- CAS No.: 2414962-49-3
- Formula:N/A
- Molecular Weight:(144 kDa)
SMILES: [Sirexatamab]
Biological Activity: Sirexatamab (DKN-01; LY-2812176) is a humanized IgG4 monoclonal antibody targeting DKK1, with Kd values of 3.3 pM and 20 pM for human and murine (mDKN-01) forms, respectively. Sirexatamab binds to DKK1 to neutralize its activity and reverse the inhibition of the canonical Wnt/β-catenin signaling pathway. Sirexatamab can be used in research related to cancers such as non-small cell lung cancer, endometrial cancer, and ovarian cancer[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Sirexatamab | 99.84% | Sirexatamab (DKN-01; LY-2812176) is a humanized IgG4 monoclonal antibody targeting DKK1, with Kd values of 3.3 pM and 20 pM for human and murine (mDKN-01) forms, respectively. Sirexatamab binds to DKK1 to neutralize its activity and reverse the inhibition of the canonical Wnt/β-catenin signaling pathway. Sirexatamab can be used in research related to cancers such as non-small cell lung cancer, endometrial cancer, and ovarian cancer. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Wall JA, et al. The anti-DKK1 antibody DKN-01 as an immunomodulatory combination partner for the treatment of cancer. Expert opinion on investigational drugs. 2020 Jul;29(7):639-644. [Content Brief]
-
[2]. Haas, M. S., et al. (2021). mDKN-01, a novel anti-DKK1 mAb, enhances innate immune responses in the tumor microenvironment. Molecular Cancer Research, 19(4), 717-725.
Keywords
